The study, published in Genetics in Medicine, analyzed over 200 cases to bridge a significant knowledge gap in prenatal care. While noninvasive cfDNA screening is standard for detecting common chromosomal abnormalities like Down syndrome, atypical results often leave clinicians and patients in a state of uncertainty, unsure whether the signal points to a fetal concern, a maternal genetic issue, or a benign variation.
In section Releases
New Research Validates Clinical Significance of Atypical Prenatal DNA Tests
Atypical results from prenatal cell-free DNA screening are far from clinical dead ends, according to a decade-long study by ARUP Laboratories. Researchers found that half of all atypical findings correlate with abnormal diagnostic results, providing a crucial roadmap for healthcare providers managing high-risk pregnancies and maternal health outcomes.
Data indicates that 50% of the atypical cases studied led to at least one abnormal finding upon follow-up testing. Among these, 55 results were confirmed as pathogenic. Copy number variations emerged as the most frequent diagnostic finding, though the team also identified instances of aneuploidy and chromosome rearrangements. Crucially, the research highlights that these atypical signals may reveal maternal genetic anomalies rather than fetal ones, suggesting that maternal testing could serve as a valuable intermediary step before opting for invasive procedures like amniocentesis.
Comments (0)
No comments yet. Be the first!